Drug Profile
Research programme: JAK inhibitors - Celon Pharma
Alternative Names: CPL 407 22; CPL 407 405; CPL-407-105Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Celon Pharma
- Class Small molecules
- Mechanism of Action Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Asthma; Myeloproliferative disorders
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for research development in Acute-myeloid-leukaemia in Poland
- 28 Jul 2018 No recent reports of development identified for research development in Asthma in Poland
- 28 Jul 2018 No recent reports of development identified for research development in Myeloproliferative disorders in Poland